BSE:509079

Stock Analysis Report

Executive Summary

Gufic Biosciences Limited engages in the manufacture and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services in India.

Snowflake

Fundamentals

Solid track record with mediocre balance sheet.

Share Price & News

How has Gufic Biosciences's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-3.3%

509079

3.0%

IN Pharmaceuticals

3.1%

IN Market


1 Year Return

-28.1%

509079

-18.9%

IN Pharmaceuticals

3.7%

IN Market

Return vs Industry: 509079 underperformed the Indian Pharmaceuticals industry which returned -18.9% over the past year.

Return vs Market: 509079 underperformed the Indian Market which returned 3.7% over the past year.


Shareholder returns

509079IndustryMarket
7 Day-3.3%3.0%3.1%
30 Day7.0%-4.2%5.7%
90 Day3.9%-2.5%1.4%
1 Year-28.1%-28.1%-18.2%-18.9%5.9%3.7%
3 Year74.7%74.4%-26.1%-27.6%22.3%16.0%
5 Year325.3%323.3%-11.7%-14.3%42.5%28.9%

Price Volatility Vs. Market

How volatile is Gufic Biosciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Gufic Biosciences undervalued compared to its fair value and its price relative to the market?

22.33x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Undervalued: 509079 (₹71.75) is trading above our estimate of fair value (₹0.73)

Significantly Undervalued: 509079 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 509079 is poor value based on its PE Ratio (22.3x) compared to the Pharmaceuticals industry average (15.8x).

PE vs Market: 509079 is poor value based on its PE Ratio (22.3x) compared to the Indian market (13.2x).


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate 509079's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 509079 is overvalued based on its PB Ratio (7.4x) compared to the IN Pharmaceuticals industry average (1.5x).


Next Steps

Future Growth

How is Gufic Biosciences forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

-2.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 509079's earnings are forecast to decline over the next 3 years (-2.5% per year).

Earnings vs Market: 509079's earnings are forecast to decline over the next 3 years (-2.5% per year).

High Growth Earnings: 509079's earnings are forecast to decline over the next 3 years.

Revenue vs Market: Insufficient data to determine if 509079's revenue is forecast to grow faster than the Indian market.

High Growth Revenue: Insufficient data to determine if 509079's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if 509079's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Gufic Biosciences performed over the past 5 years?

34.9%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: 509079's earnings have grown significantly by 34.9% per year over the past 5 years.

Accelerating Growth: 509079's earnings growth over the past year (51.7%) exceeds its 5-year average (34.9% per year).

Earnings vs Industry: 509079 earnings growth over the past year (51.7%) exceeded the Pharmaceuticals industry 14.4%.


Return on Equity

High ROE: Whilst 509079's Return on Equity (33.03%) is high, this metric is skewed due to their high level of debt.


Return on Assets

ROA vs Industry: 509079 has a higher Return on Assets than the Pharmaceuticals industry average last year.


Return on Capital Employed

ROCE Improving: 509079 has significantly improved its Return on Capital Employed over the past 3 years.


Next Steps

Financial Health

How is Gufic Biosciences's financial position?


Financial Position Analysis

Short Term Liabilities: 509079's short term assets (₹2.3B) exceeds its short term liabilities (₹1.9B)

Long Term Liabilities: 509079's short term assets (2.3B) exceeds its long term liabilities (178.4M)


Debt to Equity History and Analysis

Debt Level: 509079's debt to equity ratio (127.4%) is considered high

Reducing Debt: 509079's debt to equity ratio has increased from 113.1% to 127.4% over the past 5 years.

Debt Coverage: 509079's debt is not well covered by operating cash flow (5.4%).

Interest Coverage: 509079's interest payments on its debt are well covered by EBIT (4x coverage).


Balance Sheet

Inventory Level: 509079 has a high level of physical assets or inventory.

Debt Coverage by Assets: 509079's debt is covered by short term assets (assets are 2.422920x debt).


Next Steps

Dividend

What is Gufic Biosciences's current dividend yield, its reliability and sustainability?

0.068%

Current Dividend Yield


Dividend Yield vs Market

company0.07%marketbottom25%0.6%markettop25%2.5%industryaverage0.9%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: 509079's dividend (0.068%) isn’t notable compared to the bottom 25% of dividend payers in the Indian market (0.6%).

High Dividend: 509079's dividend (0.068%) is low compared to the top 25% of dividend payers in the Indian market (2.48%).

Stable Dividend: 509079 is not paying a notable dividend for the Indian market, therefore no need to check if payments are stable.

Growing Dividend: 509079 is not paying a notable dividend for the Indian market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: 509079 is not paying a notable dividend for the Indian market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 509079's dividend in 3 years as they are not forecast to pay a notable one for the Indian market.


Next Steps

Management

What is the CEO of Gufic Biosciences's salary, the management and board of directors tenure and is there insider trading?

3.9yrs

Average board tenure


CEO

Pranav Choksi (36yo)

0yrs

Tenure

₹2,355,175

Compensation

Mr. Pranav Jayesh Choksi has been an Executive Whole Time Director of Gufic Biosciences Ltd. since June 25, 2004 and serves as its Chief Executive Officer. Mr. Choksi serves as Chief Executive Officer & Wh ...


CEO Compensation Analysis

Compensation vs. Market: Pranav's total compensation ($USD33.13K) is too low to compare against companies of similar size in the Indian market ($USD28.94K).

Compensation vs Earnings: Pranav's compensation has been consistent with company performance over the past year.


Board Age and Tenure

3.9yrs

Average Tenure

60.5yo

Average Age

Experienced Board: 509079's board of directors are considered experienced (3.9 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Jayesh Choksi (65yo)

    Chairman & MD

    • Tenure: 0yrs
    • Compensation: ₹4.00m
  • Pranav Choksi (36yo)

    CEO & Whole Time Director

    • Tenure: 0yrs
    • Compensation: ₹2.36m
  • Pankaj Gandhi (60yo)

    Whole-Time Director

    • Tenure: 6.2yrs
    • Compensation: ₹936.33k
  • Hemal Desai (53yo)

    Whole-Time Director

    • Tenure: 4.9yrs
    • Compensation: ₹903.92k
  • Ami Shah

    Company Secretary

    • Tenure: 0yrs
    • Compensation: ₹696.61k
  • Debesh Das

    Vice-President of Ethical Sales & Marketing

    • Tenure: 4.7yrs
    • Compensation: ₹4.42m
  • Devkinandan Roonghta (54yo)

    Chief Financial Officer

    • Tenure: 1yrs
    • Compensation: ₹1.76m

Board Members

  • Jayesh Choksi (65yo)

    Chairman & MD

    • Tenure: 0yrs
    • Compensation: ₹4.00m
  • Pranav Choksi (36yo)

    CEO & Whole Time Director

    • Tenure: 0yrs
    • Compensation: ₹2.36m
  • Pankaj Gandhi (60yo)

    Whole-Time Director

    • Tenure: 6.2yrs
    • Compensation: ₹936.33k
  • Shreyas Patel (57yo)

    Non Executive Independent Director

    • Tenure: 5.2yrs
    • Compensation: ₹40.00k
  • Hemal Desai (53yo)

    Whole-Time Director

    • Tenure: 4.9yrs
    • Compensation: ₹903.92k
  • Gopal Daptari (70yo)

    Independent Director

    • Tenure: 2.9yrs
    • Compensation: ₹15.00k
  • Shrirang Vaidya (63yo)

    Independent Director

    • Tenure: 1.7yrs
    • Compensation: ₹45.00k
  • Balram Singh (61yo)

    Non-Executive & Non Independent Director

    • Tenure: 1.4yrs
  • Rabi Sahoo

    Non-Executive Independent Director

    • Tenure: 0.3yrs

Company Information

Gufic Biosciences Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Gufic Biosciences Limited
  • Ticker: 509079
  • Exchange: BSE
  • Founded: 1970
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₹5.612b
  • Shares outstanding: 77.83m
  • Website: https://gufic.com

Number of Employees


Location

  • Gufic Biosciences Limited
  • SM House
  • 1st to 4th Floor
  • Mumbai
  • Maharashtra
  • 400057
  • India

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
509079BSE (Mumbai Stock Exchange)YesEquity SharesININRMar 2001
GUFICBIONSEI (National Stock Exchange of India)YesEquity SharesININRMar 2001

Biography

Gufic Biosciences Limited engages in the manufacture and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services in India. It manufactures active pharmaceutical ingred ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/18 12:40
End of Day Share Price2019/10/18 00:00
Earnings2019/06/30
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.